Antibodies as Drugs: Engineering Next-Generation Therapeutics

Feb 07–10, 2028 | La Fonda on the Plaza, Santa Fe, NM, United States
Scientific Organizers: Christian Klein, Janine Schuurman, and Mark S Cragg

  Livestream
  In Person
  On Demand
×

-

Feb 07–10, 2028 | La Fonda on the Plaza, Santa Fe, NM, United States

Scientific Organizers: Christian Klein, Janine Schuurman, and Mark S Cragg

Supported by:  

***Meeting program subject to change.

Available Formats:     = Livestream   = In Person     = On Demand
Monday, February 7, 2028
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Tuesday, February 8, 2028
Breakfast
7:30–8:30 AM
Poster Setup
8:00–8:30 AM
Poster Viewing
8:15–5:00 PM
Welcome Remarks
8:30–8:40 AM
Keynote Address
8:40–9:30 AM
James A Wells, University of California, San Francisco
Antibody-based Degraders
Next Generation T Cell Engagers
9:30–11:45 AM
Christian Klein, Biotech Startup
Progress with T Cell Engagement
Geetha Shankar †, Vir Biotechnology, Inc.
Progress with Tumor-Activated T Cell Engagers
Burcu Yigit, Cartography Biosciences
Discovery of Novel Selective Targets for T Cell Engagers
Short Talk(s) Chosen from Abstracts
Coffee Break
10:00–10:20 AM
Posters
12:30–2:30 PM
Lunch
12:55–1:55 PM
Symposia Spotlight 1: Therapeutic Antibodies for Oncology, I&I, Metabolism, CNS, and Infection
2:30–4:30 PM
* Christian Klein, Biotech Startup
* Janine Schuurman, Lust for Life Science
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Computational Design and Lab-in-the-Loop Engineering of Biologics
5:00–7:00 PM
Charlotte Deane †, University of Oxford
In silico Design of CDRs
Sarel J. Fleishman †, Weizmann Institute of Science
Energy-Guided Combinatorial Co-Optimization of Antibody Affinity and Stability
Peyton Greenside †, BigHat Biosciences
Antibody Learning Loop: Prediction and Experimental Validation/Optimization
Short Talk(s) Chosen from Abstracts
On Own for Dinner
7:00–8:00 PM
Wednesday, February 9, 2028
Breakfast
7:30–8:30 AM
Poster Setup
8:00–8:30 AM
Poster Viewing
8:15–5:00 PM
Mechanisms of Action
8:30–11:30 AM
Janine Schuurman, Lust for Life Science
Overview on Novel MOAs for Antibody-based Therapies
Pamela M. Holland †, InduPro
Making use of Proximity for Novel cis-Targeted Antibody MOAs
Stefan Zielonka †, Clemens-Schöpf-Institut, Technische Universität Darmstadt
VHH-based Antibody Mimetics
Rony Dahan †, Weizmann Institute of Science
Bi- and Tri-specific Antibodies Linking Innate and Adaptive Immunity
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Lunch
11:30–12:30 PM
Posters
12:30–2:30 PM
Career Roundtable
3:00–4:30 PM
Coffee Available
4:30–5:00 PM
Antibody Drug Conjugates and Radioimmunotherapy
5:00–7:00 PM
Raffaele Colombo †, Zymeworks Inc.
The Evolution of Antibody Drug Conjugates
Andrew Souers †, AbbVie
Degrader Antibody Conjugates Targeting Bcl Family Members
Sofia Frost †, Roche
Novel Split Pre-Targeted Radioimmunotherapy
Short Talk(s) Chosen from Abstracts
On Own for Dinner
7:00–8:00 PM
Thursday, February 10, 2028
Breakfast
7:30–8:30 AM
Approaches for Autoimmunity, Infectious Diseases, and CNS Diseases
8:30–11:30 AM
Joy Yu Zuchero, Denali Therapeutics Inc
Delivering Antibodies Over the Blood Brain Barrier for CNS Diseases
Robert A. Seder, NIAID, National Institutes of Health
Developing Long-Acting Antibodies for Malaria
Chris Paluch †, Gilead Sciences
Antibody Agonists for AID
Lucy Dorrell †, Immunocore
Targeting HIV Gag77-85 for Eradication with a Bispecific TCR ImmTac
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Panel Discussion: Where are Next Generation Antibodies and Design Heading?
11:40–12:40 PM
Lunch
12:40–1:40 PM
Symposia Spotlight 2: AI/ML in Antibody Engineering
2:30–4:30 PM
* Mark S Cragg, University of Southampton
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Therapeutic Innovation with Engineered Antibodies
5:00–6:45 PM
Ricardo Grieshaber-Bouyer, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen
Cell Depletion Approaches in Autoimmune Diseases
Mark S Cragg, University of Southampton
Engineering Antibodies for Receptor Agonism
Susan M. Galbraith †, AstraZeneca
Clinical Progress with Antibody Drug Conjugates
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions
6:45–7:00 PM
On Own for Dinner
7:00–8:00 PM
Friday, February 11, 2028
Departure
12:00–11:59 PM

Subscribe for Updates